<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01709396</url>
  </required_header>
  <id_info>
    <org_study_id>2011064-01</org_study_id>
    <nct_id>NCT01709396</nct_id>
  </id_info>
  <brief_title>ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS</brief_title>
  <acronym>ED-TBI</acronym>
  <official_title>Extended Dose - Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory Acute Leukemia And Advanced Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia (AML) is a rapidly fatal malignancy of the bone marrow. It can be&#xD;
      treated with chemotherapy alone, in some cases, but in the majority of cases, the only&#xD;
      treatment that can cure the disease is an allogeneic stem cell transplant, with a cure rate&#xD;
      of 30-40%. In another subset, the disease is less responsive to chemotherapy and in these&#xD;
      aggressive forms, its cure rate is no better than 20% beyond 2 years, and is usually rapidly&#xD;
      fatal within 6 months.&#xD;
&#xD;
      Therefore, for this most aggressive form of the disease, modifications to the transplant&#xD;
      protocol are required in order to try to improve on these poor results. There are a number of&#xD;
      areas within the transplant protocol on which modifications can be made in order to achieve&#xD;
      these goals. These include: higher doses of chemotherapy and or radiation; alterations of the&#xD;
      new bone marrow graft; and alterations of the immune suppression, enhancing the graft vs.&#xD;
      leukemia effect. By focusing on one or more of these components, one might be able to enhance&#xD;
      the anti-leukemic aspect of the treatment resulting in a more successful outcome.&#xD;
&#xD;
      One aspect the investigators, in Ottawa, have focused on is the initial intensive&#xD;
      conditioning regimen, specifically the radiation component. It is the investigators belief&#xD;
      that in the most resistant disease it is important to use the highest tolerable anti-leukemic&#xD;
      treatment upfront, specifically, enhancing the radiation component of the initial&#xD;
      conditioning regimen. Previous studies have suggested that higher doses of radiation might be&#xD;
      more effective at eliminating the disease, however, toxicity and logistics of delivering the&#xD;
      radiation have limited its use. Technical advances in the delivery of radiation have now&#xD;
      permitted the safer use of high doses of radiation.&#xD;
&#xD;
      Through modifications to the transplant procedure, the investigators believe that they can&#xD;
      deliver higher doses of radiation safely and this will translate into improved outcomes in&#xD;
      this high-risk subgroup of patients with AML.&#xD;
&#xD;
      Study Objectives&#xD;
&#xD;
      The goal of this study is to determine if a total dose of 18Gy ED-TBI followed by an alloHSCT&#xD;
      for patients with refractory AML will result in an improved progression-free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Rationale&#xD;
&#xD;
        1. AML is a bone marrow based malignancy that is rapidly growing and rapidly fatal if left&#xD;
           untreated. Despite therapeutic strategies for up to 70% of patients, 20% are primarily&#xD;
           refractory and another 50% will relapse after first line therapy. Among these refractory&#xD;
           and relapsed patients the only, potentially, effective therapy is an alloHSCT, however,&#xD;
           long-term survival rates range from as low as &lt;10% up to 20%.&#xD;
&#xD;
        2. Increased doses of radiation in the form of TBI to a threshold of 15.75 Gy with&#xD;
           chemotherapy have been demonstrated to reduce the relapse rate significantly; however,&#xD;
           OS is compromised by the high rate of toxicity.&#xD;
&#xD;
        3. Evidence suggests that escalated doses of radiation are possible, which offers the&#xD;
           potential to increase the dose of radiation to as much as 20Gy, safely.&#xD;
&#xD;
        4. Locally, increased doses of radiation without chemotherapy did not demonstrate any&#xD;
           significant toxicity up to a dose of 16Gy.&#xD;
&#xD;
        5. Therefore, as proposed a radiation-only stem cell transplant would allow us to test the&#xD;
           hypothesis that increased doses of radiation will reduce the relapse rate while&#xD;
           minimizing the toxicity in a very high-risk population of patients with AML, resulting&#xD;
           in an improved progression-free and overall survival.&#xD;
&#xD;
      Trial Design&#xD;
&#xD;
      This is a single institution, Phase II study examining the efficacy and toxicity of ED-TBI&#xD;
      followed by an alloHSCT on patients with high risk, refractory acute myeloid leukemia.&#xD;
&#xD;
      Treatment Overview&#xD;
&#xD;
      Patients who have met the inclusion criteria will receive a myeloablative dose of radiation&#xD;
      followed by an alloHSCT. Acute radiation and transplant related toxicity will be evaluated as&#xD;
      the maximum value on the National Cancer Institute Common Terminology Criteria for Adverse&#xD;
      Events, version 4.0 (CTCAE v.4), during the first 30 days following the transplantation and&#xD;
      the LENT-SOMA Radiation Toxicity Scale. The radiation dose to the lungs and kidneys as well&#xD;
      as the total dose received by the other organs will be considered independently for the&#xD;
      purposes of determining the maximum tolerated radiation dose for that body region.&#xD;
&#xD;
      Eligibility Assessments&#xD;
&#xD;
      Assessments to determine the eligibility to participate in this study will be performed&#xD;
      before enrollment in the study, but after the subject has signed the informed consent.&#xD;
      Subjects who do not meet the eligibility criteria will be considered screening failures and&#xD;
      will not be enrolled.&#xD;
&#xD;
      These assessments will determine:&#xD;
&#xD;
        -  Subject eligibility for entry on study,&#xD;
&#xD;
        -  Suitability to undergo TBI followed by an alloHSCT.&#xD;
&#xD;
        -  Pre-treatment leukemia activity.&#xD;
&#xD;
      The following pre-treatment assessments will be performed within a six-week period prior to&#xD;
      enrollment:&#xD;
&#xD;
        -  History and physical examination, including height, weight, vital signs&#xD;
&#xD;
        -  ECOG Performance Status and Karnofsky performance status (appendix #3).&#xD;
&#xD;
        -  CBC, differential, platelets, and reticulocyte count.&#xD;
&#xD;
        -  INR, PTT, fibrinogen&#xD;
&#xD;
        -  Serum electrolytes, urea, creatinine, calcium and phosphorus, AST, ALT, ALP, total&#xD;
           bilirubin and LD&#xD;
&#xD;
        -  Pre-transplant infectious disease markers:CMV serology, HIV-1 and HIV-2, HTLV-1 and&#xD;
           HTLV-2, HBsAg, Anti-HBs, Anti-HBc, Anti-HCV, Serologic Test for Syphilis (STS)&#xD;
&#xD;
        -  Electrocardiogram (ECG).&#xD;
&#xD;
        -  Echocardiogram including measurement of LVEF.&#xD;
&#xD;
        -  Pulmonary function tests including FEV1, FVC and DLCO.&#xD;
&#xD;
        -  Pregnancy test (urine or serum βHCG) on female subjects, unless they have undergone a&#xD;
           surgical procedure for sterilization or are post-menopausal (defined as more than 2&#xD;
           years have elapsed since their last menstruation in the absence of contraceptive use)&#xD;
&#xD;
        -  A bone marrow aspirate with cytogenetics with or without biopsy with molecular testing.&#xD;
&#xD;
      Study Evaluations&#xD;
&#xD;
      Baseline Assessment&#xD;
&#xD;
      Patient testing will reflect the routine clinical operating practices of the Ottawa Hospital&#xD;
      Blood and Marrow Transplant and Radiation Oncology Programs. The following measures and tests&#xD;
      will be used to evaluate the status of the leukemia prior to treatment and the patient's&#xD;
      pre-treatment organ function. They will be performed within 2 weeks of the first fraction of&#xD;
      ED-TBI .&#xD;
&#xD;
        -  History, physical examination, height and weight upon admission&#xD;
&#xD;
        -  Urinalysis&#xD;
&#xD;
        -  ECOG performance status&#xD;
&#xD;
        -  HCT-specific cd-morbidity index&#xD;
&#xD;
        -  CBC, differential&#xD;
&#xD;
        -  Serum Creatinine, bilirubin, AST, ALT, ALP.&#xD;
&#xD;
        -  INR, PTT, fibrinogen&#xD;
&#xD;
        -  TSH&#xD;
&#xD;
        -  A bone marrow aspirate with cytogenetics and molecular testing, with or without biopsy.&#xD;
&#xD;
      Post-transplant Assessments&#xD;
&#xD;
      Patient testing in the immediate period during ED-TBI and following alloHSCT will reflect the&#xD;
      clinical operating practices of the Ottawa Hospital Blood and Marrow Transplant Program. The&#xD;
      tests will be used to evaluate the severity of acute radiation toxicity, the time to&#xD;
      engraftment, GVHD etc.&#xD;
&#xD;
        -  History and physical exam to assess GVHD and other morbidity weekly until Day 100&#xD;
           post-transplant, then at four months, six months, one year, 18 months and two years&#xD;
           post-transplant.&#xD;
&#xD;
             -  Acute GVHD will be evaluated according to the grading system in appendix 8&#xD;
&#xD;
             -  Chronic GVHD will be evaluated according to the grading system in appendix 9&#xD;
&#xD;
        -  CBC at least three times a week from Day 0 until ANC &gt; 0.5 x 109/L for 3 consecutive&#xD;
           measurements over 3 or more days. Thereafter CBC at least twice per week until Day 28,&#xD;
           then preferably weekly until Day 100, then at 12 months, 18 months and two years&#xD;
           post-transplant&#xD;
&#xD;
        -  Creatinine, bilirubin, alkaline phosphatase, ALT, AST, twice a week until Day 28 and&#xD;
           then preferably weekly until 12 weeks, then at four months, six months, one year,&#xD;
           eighteen months and two years post-transplant.&#xD;
&#xD;
        -  Tacrolimus levels will be measured at least once weekly until the drug is tapered off.&#xD;
&#xD;
        -  Serum CMV-PCR weekly for at least 6 months.&#xD;
&#xD;
        -  Bone marrow aspirate and biopsy at Day 100 ±30 days on all patients. Bone marrow&#xD;
           aspirate and biopsy at 12 ±3 months post-transplant is recommended, but not required,&#xD;
           for all patients.&#xD;
&#xD;
        -  Treat-related toxicity (RRT) assessments will be conducted weekly until Day 100 and&#xD;
           additional toxicity assessments will be conducted on Day 100, 180, 365 and 730&#xD;
           post-transplant using the CTCAE V.4.&#xD;
&#xD;
        -  Weekly urinalysis until discharge and then at 6, 12, 18 and 24 months.&#xD;
&#xD;
      The following tests will be performed at 6 months following treatment and then annually until&#xD;
      2 years after the transplant&#xD;
&#xD;
        -  Bone Mineral Density&#xD;
&#xD;
        -  TSH&#xD;
&#xD;
        -  Serum Testosterone (males)&#xD;
&#xD;
        -  LENT-SOMA Radiation Toxicity Scale&#xD;
&#xD;
        -  Pulmonary Function Tests (Flow Rates, Diffusion Capacity, Lung Volumes and O2 Saturation&#xD;
           by oximetry.)&#xD;
&#xD;
      The following will be performed at any time to look for relapse, if indicated (i.e. drop in&#xD;
      the platelet count below 100 x 109 cells/L or in the neutrophil count below 1 x 109 cells/L,&#xD;
      circulating blasts &gt;0%, unrelated to treatment) or if there is any other reason to suspect&#xD;
      relapse.&#xD;
&#xD;
      -Bone marrow aspirate +/- biopsy&#xD;
&#xD;
      Other tests may be added and the frequency of the above test may be changed depending on the&#xD;
      clinical scenario during the transplant.&#xD;
&#xD;
      The following summary statistics will be obtained at the time of discharge from the alloHSCT&#xD;
      hospital admission:&#xD;
&#xD;
        -  Weight at discharge&#xD;
&#xD;
        -  Number of units of blood and platelets administered&#xD;
&#xD;
        -  Number of febrile days (t&gt;38oC)&#xD;
&#xD;
        -  Documented Infections&#xD;
&#xD;
        -  Maximum adverse events according to CTCAE v.4&#xD;
&#xD;
        -  Days admitted to the BMT Day hospital unit&#xD;
&#xD;
        -  Days admitted to the BMT Inpatient unit&#xD;
&#xD;
        -  Days admitted to the ICU&#xD;
&#xD;
        -  Length of Hospital admission&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    initial on hold due to space but now permanently suspended due to futility.&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year post allogenic transplant</time_frame>
    <description>The primary objective of this study is to determine the progression-free survival at 1 year, post alloHSCT, after ED-TBI followed by an alloHSCT for patients with refractory AML</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>Within 100 day post transplant</time_frame>
    <description>The time to neutrophil and platelet engraftment following ED-TBI and alloHSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity/Mortality</measure>
    <time_frame>day 30, day 100, day 180 post transplant</time_frame>
    <description>The day 30 morbidity (frequency, severity and affected organ function) of ED-TBI&#xD;
The day 30 mortality associated with ED-TBI and alloHSCT.&#xD;
The day 100 morbidity (frequency, severity and affected organ function) of ED-TBI&#xD;
The day 100 mortality associated with ED-TBI and alloHSCT.&#xD;
The late (&gt; 6 month and &gt;1 year) morbidity and mortality of ED-TBI/alloHSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>5 years post transplant</time_frame>
    <description>Relapse rate after alloHSCT&#xD;
The pattern of relapse (blood and marrow vs. extramedullary)&#xD;
The overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD</measure>
    <time_frame>day 30, day 100, 180, 365 and 730 post transplant</time_frame>
    <description>Incidence and severity of acute and chronic GVHD</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of Safety</measure>
    <time_frame>day 30, day 100, 180, 365 and 730 post transplant</time_frame>
    <description>All patients who receive at least one fraction of ED-TBI will be used in the safety analysis.&#xD;
The incidence of adverse and serious adverse events will be tabulated by, severity and relationship to the treatment.&#xD;
Adverse and serious adverse events will be monitored on an ongoing basis by the investigators.&#xD;
Adverse events will be categorized using the CTCAE v.4. Adverse events will be summarized at the following intervals post stem cell transplant: day 30, day 100, 180, 365 and 730.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Efficacy</measure>
    <time_frame>day 30, day 100, 180, 365 and 730 post transplant</time_frame>
    <description>Objective data to determine CR rate, rate of relapse, time-to-progression and overall survival will be collected and reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Study</measure>
    <time_frame>2-3 years</time_frame>
    <description>Approximately, 5 patients from our institution will be eligible per year. Additional patients from cooperating centers could, potentially, add another 5 patients/year. Therefore, the duration of accrual is expected to be between 2-3 years.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>18 cGY ED-TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 cGY ED-TBI followed by an allogenic done marrow transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>ED-TBI</intervention_name>
    <description>Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.</description>
    <arm_group_label>18 cGY ED-TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  All subjects must meet all of the following criteria to be eligible for the study.&#xD;
             These will be evaluated within the four weeks prior to enrolment.&#xD;
&#xD;
          -  Subject must have primary refractory AML, secondary AML, relapsed AML or high risk MDS&#xD;
&#xD;
          -  Primary refractory AML is defined as:&#xD;
&#xD;
        A blast count in the bone marrow of &gt;5% or the presence of any amount of circulating&#xD;
        blasts, in the peripheral blood, after 1 cycle of induction chemotherapy.&#xD;
&#xD;
          -  Secondary AML is defined as:&#xD;
&#xD;
        AML, except acute promyelocytic leukemia, arising from any haematological disease or from&#xD;
        the exposure to chemotherapy for another unrelated malignancy.&#xD;
&#xD;
          -  Relapsed AML is defined as:&#xD;
&#xD;
        Relapse (&gt;5% blasts in the marrow) after having achieved a CR, of any duration.&#xD;
&#xD;
          -  High risk myelodysplasia is defined as:&#xD;
&#xD;
        Myelodysplastic syndrome as defined by the WHO criteria with an international prognostic&#xD;
        score (IPSS) of intermediate-2 or high&#xD;
&#xD;
          -  Subjects must have a score of ≥2 on the scoring system for hematopoietic stem-cell&#xD;
             transplantation for acute leukemia in relapse or primary induction failure&#xD;
&#xD;
          -  Subjects must meet institutional guidelines for an alloHSCT.&#xD;
&#xD;
          -  Subjects must have a matched related or a well- or partially-matched unrelated donor,&#xD;
             acceptable to institutional guidelines who can donate either peripheral blood or bone&#xD;
             marrow hematopoietic stem cells.&#xD;
&#xD;
          -  Subjects must be of age ≥18 and ≤60 years.&#xD;
&#xD;
          -  Subjects must have an ECOG performance score of 0,1, or 2&#xD;
&#xD;
          -  Subjects must have the ability to comply with the protocol visit schedule and other&#xD;
             protocol requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subjects who have a score of &lt; 2 on the scoring system for hematopoietic stem-cell&#xD;
             transplantation for acute leukemia in relapse or primary induction failure&#xD;
&#xD;
          -  Subjects who previously received an autoHSCT or alloHSCT&#xD;
&#xD;
          -  Subjects who have previously received radiation therapy&#xD;
&#xD;
          -  Subjects with a prior nephrectomy or a known history of a single kidney.&#xD;
&#xD;
          -  Subjects with HIV-seropositivity.&#xD;
&#xD;
          -  Subjects with a recent history of alcohol or drug abuse.&#xD;
&#xD;
          -  Pregnant or lactating female subjects.&#xD;
&#xD;
          -  Subject whose only donor is an umbilical cord donor&#xD;
&#xD;
          -  Subjects whose only donor is an unrelated mismatched donor, according the recently&#xD;
             published CIBMTR criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Sabloff</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital - Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ohri.ca/</url>
    <description>Ottawa Hospital Research Institute</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2012</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01709396
org study id: 2011064-01
nct id: NCT01709396
lead sponsor: 
has dmc: Yes
Acute myeloid leukemia (AML) is a rapidly fatal malignancy of the bone marrow. It can be
      treated with chemotherapy alone, in some cases, but in the majority of cases, the only
      treatment that can cure the disease is an allogeneic stem cell transplant, with a cure rate
      of 30-40%. In another subset, the disease is less responsive to chemotherapy and in these
      aggressive forms, its cure rate is no better than 20% beyond 2 years, and is usually rapidly
      fatal within 6 months.

      Therefore, for this most aggressive form of the disease, modifications to the transplant
      protocol are required in order to try to improve on these poor results. There are a number of
      areas within the transplant protocol on which modifications can be made in order to achieve
      these goals. These include: higher doses of chemotherapy and or radiation; alterations of the
      new bone marrow graft; and alterations of the immune suppression, enhancing the graft vs.
      leukemia effect. By focusing on one or more of these components, one might be able to enhance
      the anti-leukemic aspect of the treatment resulting in a more successful outcome.

      One aspect the investigators, in Ottawa, have focused on is the initial intensive
      conditioning regimen, specifically the radiation component. It is the investigators belief
      that in the most resistant disease it is important to use the highest tolerable anti-leukemic
      treatment upfront, specifically, enhancing the radiation component of the initial
      conditioning regimen. Previous studies have suggested that higher doses of radiation might be
      more effective at eliminating the disease, however, toxicity and logistics of delivering the
      radiation have limited its use. Technical advances in the delivery of radiation have now
      permitted the safer use of high doses of radiation.

      Through modifications to the transplant procedure, the investigators believe that they can
      deliver higher doses of radiation safely and this will translate into improved outcomes in
      this high-risk subgroup of patients with AML.

      Study Objectives

      The goal of this study is to determine if a total dose of 18Gy ED-TBI followed by an alloHSCT
      for patients with refractory AML will result in an improved progression-free survival.
Study Rationale

        1. AML is a bone marrow based malignancy that is rapidly growing and rapidly fatal if left
           untreated. Despite therapeutic strategies for up to 70% of patients, 20% are primarily
           refractory and another 50% will relapse after first line therapy. Among these refractory
           and relapsed patients the only, potentially, effective therapy is an alloHSCT, however,
           long-term survival rates range from as low as <10% up to 20%.

        2. Increased doses of radiation in the form of TBI to a threshold of 15.75 Gy with
           chemotherapy have been demonstrated to reduce the relapse rate significantly; however,
           OS is compromised by the high rate of toxicity.

        3. Evidence suggests that escalated doses of radiation are possible, which offers the
           potential to increase the dose of radiation to as much as 20Gy, safely.

        4. Locally, increased doses of radiation without chemotherapy did not demonstrate any
           significant toxicity up to a dose of 16Gy.

        5. Therefore, as proposed a radiation-only stem cell transplant would allow us to test the
           hypothesis that increased doses of radiation will reduce the relapse rate while
           minimizing the toxicity in a very high-risk population of patients with AML, resulting
           in an improved progression-free and overall survival.

      Trial Design

      This is a single institution, Phase II study examining the efficacy and toxicity of ED-TBI
      followed by an alloHSCT on patients with high risk, refractory acute myeloid leukemia.

      Treatment Overview

      Patients who have met the inclusion criteria will receive a myeloablative dose of radiation
      followed by an alloHSCT. Acute radiation and transplant related toxicity will be evaluated as
      the maximum value on the National Cancer Institute Common Terminology Criteria for Adverse
      Events, version 4.0 (CTCAE v.4), during the first 30 days following the transplantation and
      the LENT-SOMA Radiation Toxicity Scale. The radiation dose to the lungs and kidneys as well
      as the total dose received by the other organs will be considered independently for the
      purposes of determining the maximum tolerated radiation dose for that body region.

      Eligibility Assessments

      Assessments to determine the eligibility to participate in this study will be performed
      before enrollment in the study, but after the subject has signed the informed consent.
      Subjects who do not meet the eligibility criteria will be considered screening failures and
      will not be enrolled.

      These assessments will determine:

        -  Subject eligibility for entry on study,

        -  Suitability to undergo TBI followed by an alloHSCT.

        -  Pre-treatment leukemia activity.

      The following pre-treatment assessments will be performed within a six-week period prior to
      enrollment:

        -  History and physical examination, including height, weight, vital signs

        -  ECOG Performance Status and Karnofsky performance status (appendix #3).

        -  CBC, differential, platelets, and reticulocyte count.

        -  INR, PTT, fibrinogen

        -  Serum electrolytes, urea, creatinine, calcium and phosphorus, AST, ALT, ALP, total
           bilirubin and LD

        -  Pre-transplant infectious disease markers:CMV serology, HIV-1 and HIV-2, HTLV-1 and
           HTLV-2, HBsAg, Anti-HBs, Anti-HBc, Anti-HCV, Serologic Test for Syphilis (STS)

        -  Electrocardiogram (ECG).

        -  Echocardiogram including measurement of LVEF.

        -  Pulmonary function tests including FEV1, FVC and DLCO.

        -  Pregnancy test (urine or serum βHCG) on female subjects, unless they have undergone a
           surgical procedure for sterilization or are post-menopausal (defined as more than 2
           years have elapsed since their last menstruation in the absence of contraceptive use)

        -  A bone marrow aspirate with cytogenetics with or without biopsy with molecular testing.

      Study Evaluations

      Baseline Assessment

      Patient testing will reflect the routine clinical operating practices of the Ottawa Hospital
      Blood and Marrow Transplant and Radiation Oncology Programs. The following measures and tests
      will be used to evaluate the status of the leukemia prior to treatment and the patient's
      pre-treatment organ function. They will be performed within 2 weeks of the first fraction of
      ED-TBI .

        -  History, physical examination, height and weight upon admission

        -  Urinalysis

        -  ECOG performance status

        -  HCT-specific cd-morbidity index

        -  CBC, differential

        -  Serum Creatinine, bilirubin, AST, ALT, ALP.

        -  INR, PTT, fibrinogen

        -  TSH

        -  A bone marrow aspirate with cytogenetics and molecular testing, with or without biopsy.

      Post-transplant Assessments

      Patient testing in the immediate period during ED-TBI and following alloHSCT will reflect the
      clinical operating practices of the Ottawa Hospital Blood and Marrow Transplant Program. The
      tests will be used to evaluate the severity of acute radiation toxicity, the time to
      engraftment, GVHD etc.

        -  History and physical exam to assess GVHD and other morbidity weekly until Day 100
           post-transplant, then at four months, six months, one year, 18 months and two years
           post-transplant.

             -  Acute GVHD will be evaluated according to the grading system in appendix 8

             -  Chronic GVHD will be evaluated according to the grading system in appendix 9

        -  CBC at least three times a week from Day 0 until ANC > 0.5 x 109/L for 3 consecutive
           measurements over 3 or more days. Thereafter CBC at least twice per week until Day 28,
           then preferably weekly until Day 100, then at 12 months, 18 months and two years
           post-transplant

        -  Creatinine, bilirubin, alkaline phosphatase, ALT, AST, twice a week until Day 28 and
           then preferably weekly until 12 weeks, then at four months, six months, one year,
           eighteen months and two years post-transplant.

        -  Tacrolimus levels will be measured at least once weekly until the drug is tapered off.

        -  Serum CMV-PCR weekly for at least 6 months.

        -  Bone marrow aspirate and biopsy at Day 100 ±30 days on all patients. Bone marrow
           aspirate and biopsy at 12 ±3 months post-transplant is recommended, but not required,
           for all patients.

        -  Treat-related toxicity (RRT) assessments will be conducted weekly until Day 100 and
           additional toxicity assessments will be conducted on Day 100, 180, 365 and 730
           post-transplant using the CTCAE V.4.

        -  Weekly urinalysis until discharge and then at 6, 12, 18 and 24 months.

      The following tests will be performed at 6 months following treatment and then annually until
      2 years after the transplant

        -  Bone Mineral Density

        -  TSH

        -  Serum Testosterone (males)

        -  LENT-SOMA Radiation Toxicity Scale

        -  Pulmonary Function Tests (Flow Rates, Diffusion Capacity, Lung Volumes and O2 Saturation
           by oximetry.)

      The following will be performed at any time to look for relapse, if indicated (i.e. drop in
      the platelet count below 100 x 109 cells/L or in the neutrophil count below 1 x 109 cells/L,
      circulating blasts >0%, unrelated to treatment) or if there is any other reason to suspect
      relapse.

      -Bone marrow aspirate +/- biopsy

      Other tests may be added and the frequency of the above test may be changed depending on the
      clinical scenario during the transplant.

      The following summary statistics will be obtained at the time of discharge from the alloHSCT
      hospital admission:

        -  Weight at discharge

        -  Number of units of blood and platelets administered

        -  Number of febrile days (t>38oC)

        -  Documented Infections

        -  Maximum adverse events according to CTCAE v.4

        -  Days admitted to the BMT Day hospital unit

        -  Days admitted to the BMT Inpatient unit

        -  Days admitted to the ICU

        -  Length of Hospital admission
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Progression-free survival
time frame: 1 year post allogenic transplant
description: The primary objective of this study is to determine the progression-free survival at 1 year, post alloHSCT, after ED-TBI followed by an alloHSCT for patients with refractory AML
measure: Engraftment
time frame: Within 100 day post transplant
description: The time to neutrophil and platelet engraftment following ED-TBI and alloHSCT
measure: Morbidity/Mortality
time frame: day 30, day 100, day 180 post transplant
description: The day 30 morbidity (frequency, severity and affected organ function) of ED-TBI
The day 30 mortality associated with ED-TBI and alloHSCT.
The day 100 morbidity (frequency, severity and affected organ function) of ED-TBI
The day 100 mortality associated with ED-TBI and alloHSCT.
The late (> 6 month and >1 year) morbidity and mortality of ED-TBI/alloHSCT
measure: Relapse
time frame: 5 years post transplant
description: Relapse rate after alloHSCT
The pattern of relapse (blood and marrow vs. extramedullary)
The overall survival
measure: GVHD
time frame: day 30, day 100, 180, 365 and 730 post transplant
description: Incidence and severity of acute and chronic GVHD
measure: Evaluation of Safety
time frame: day 30, day 100, 180, 365 and 730 post transplant
description: All patients who receive at least one fraction of ED-TBI will be used in the safety analysis.
The incidence of adverse and serious adverse events will be tabulated by, severity and relationship to the treatment.
Adverse and serious adverse events will be monitored on an ongoing basis by the investigators.
Adverse events will be categorized using the CTCAE v.4. Adverse events will be summarized at the following intervals post stem cell transplant: day 30, day 100, 180, 365 and 730.
measure: Evaluation of Efficacy
time frame: day 30, day 100, 180, 365 and 730 post transplant
description: Objective data to determine CR rate, rate of relapse, time-to-progression and overall survival will be collected and reported.
measure: Duration of Study
time frame: 2-3 years
description: Approximately, 5 patients from our institution will be eligible per year. Additional patients from cooperating centers could, potentially, add another 5 patients/year. Therefore, the duration of accrual is expected to be between 2-3 years.
arm group label: 18 cGY ED-TBI
arm group type: Experimental
description: 18 cGY ED-TBI followed by an allogenic done marrow transplant
intervention type: Radiation
intervention name: ED-TBI
description: Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
arm group label: 18 cGY ED-TBI
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: No
last name: Mitchell Sabloff
role: Principal Investigator
affiliation: The Ottawa Hospital - Ottawa Hospital Research Institute
facility: 
country: Canada
url: http://www.ohri.ca/
description: Ottawa Hospital Research Institute
responsible party type: Sponsor
mesh term: Leukemia
mesh term: Preleukemia
mesh term: Myelodysplastic Syndromes
mesh term: Syndrome
sharing ipd: Undecided